China in Africa

 

China-US team explores „nanorobots“ to seek and destroy tumors

Feb 13, 2018

The groups of Baoquan DING and colleagues at the National Center for Nanoscience and Technology (NCNST) in Beijing and of Hao YAN at Arizona State University have constructed DNA origami decorated with a DNA aptamer which specifically binds to nucleolin, a protein expressed on tumor-associated endothelial cells. The DNA origami contains thrombin which coagulates blood, thus inhibiting blood supply. When such vectors were i.v. injected to tumor-bearing mice, they were shown aggregate within 1 hour at the tumor, generated tumor tissue damage within 24 hours. Most of the nanorobots were cleared and degraded from the mouse body after 24 hours. By two days, there was evidence of advanced thrombosis, and after 3 days, thrombi in all tumor vessels were observed. in a melanoma mouse model, 3 out of 8 mice receiving the nanorobot therapy showed complete regression of the tumors. The median survival time more than doubled, extending from 20.5 to 45 days. The nanorobot proved to be safe and immunologically inert for use in normal mice and in mini pigs, showing no detectable changes in normal blood coagulation or cell morphology. There was no evidence of the nanorobots spreading into the brain (exclusion of stroke risks). CAS news release, February 13, 2018 This work, part of which was recently published in Nature Biotechnology https://www.nature.com/articles/nbt.4071, is just another example for the close cooperation of Chinese scientists in China and the USA. In fact, among the 50 million Chinese living outside China https://en.wikipedia.org/wiki/Overseas_Chinese , about 10 % live in the USA, and have often achieved leading positions in academia and business.

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

Window-to-China

Overview of last view Blogs

Genetic testing market in China big but poorly regulated.

Nov 2, 2016

Many genetic testing companies have sprung up in China. They do not only offer serious genetic testing on health, but also, e. g. the probability of appearance of bamboo shoots after a spring rain or a prediction if one’s children are gifted. Prices vary from 100 to 10,000 RMB. 70% of the genetic testing companies have no clinical relevant qualification. As there is a lack of uniform standards for genetic testing, the CFDA and the Ministry of Health are reported to work on new industry standards and rules.

China Bio news release, November 2, 2016

CAS QIBEBT establishs gene silencing technology for oil-producing microalgae

Nov 1, 2016

The group around Wei LI has used two strains Nanochloropsis oceanica and gene-silencing methods to achieve higher efficiency and specificity of carbonic anhydrase and bicarbonate transport proteins on carbon metabolism related genes, resulting in up to 40% higher yield of oil production in the engineered organisms.

CAS news release, November 9, 2016

Chongqing starts R&D base for precission medicine

Oct 31, 2016

The main organizer, Chongqing Precision Biotechnology Co., has signed into cooperation agreements with Universities in Germany and Switzerland to promote individualized medical research and therapy on cancer, autoimmune and metabolic diseases based on molecular biology research.

China Bio news release, October 31, 2016

Leaders of China’s pharmaceutical industry sign „Beijing Declaration“

Oct 31, 2016

The declaration from Chinese pharma leaders gathered in the Beijing Yizhuang Economic Development Zone is a committment to develop and produce more biotech drugs that are affordable and safe for patients in China, to solve the problem of expensive drugs for Chinese patients and to help building „healthy China 2030“.

China Bio news release, October 31, 2016

Abuse of antibiotics in human self-medication concerns doctors

Oct 31, 2016

According to a study of Zhejiang University School of Public Health, a survey on 12,000 college students in 6 provinces turned out that over 90 % of them bought antibiotics when having a cold even without diagnostic scrutiny. Many antibiotics are on sale in China over the counter and per capita consumption is 138 g, 10fold the USA. China is global leader of antibiotic production with 210,000 t, of which 30,000 t are exported.

China bio news release, October 31, 2016

CAS QIBEBT group develops Raman-based detection („ramanome“) of resistance in E. coli

Oct 31, 2016

Using single-cell Raman Spectra (SCRS) from a number of E. coli cells randomly selected from an isogenic population, sensitivity to both exposure time (eight time points) and dosage (six doses) of ethanol, n-butanol, ampicillin, kanamycin, Cu2+ and Cr6+ were analyzed. Within 5 min and at discrimination rates oveer 80 %, cytotoxicity and resistance could be identified.

CAS news release, October 31, 2016

Expert meeting on antimicrobial drug resistance in Beijing

Oct 28, 2016

In the framework of a National Action Plan against bacterial resistance (2016—2020), 200 scientists from companies and academia met in Beijing on oct. 22. The objective ist o push back the irrational use of antimicrobial drugs by better training of health workers, resistance databases and stronger legislation.

China Bio news release, October 28, 2016

State Council publishs „Healthy China 2030“ Plan

Oct 28, 2016

In 24 chapters, the plan contains an agenda to enhance health services, health protection and develop a health industry which copes with national needs. A health legal system is also envisioned.

China Bio news release, October 28, 2016

2015 Biodiesel production in China exceeded 300,000 tons

Oct 26, 2016

According to the Tianjin Institute of Industrial Biotechnology, CAS, biodiesel production in China was 336,000 tons, whereas total production capacity was 3 to 3,5 million tons. The gap is due to insufficient raw material supplies.

China Bio news release, October 26, 2016

Jinan City, Shandong, starts National R&D platform for new drugs

Oct 24, 2016

The Jinan Yao Valley biomedical industry base will focus on biological medicine, equipment, stem cell technology and precision medicine. At present, over 700 biomedical enterprises have settled in this park.

China Bio news release, October 24, 2016

Guan Hao Biotech acquires Hangzhou Huidisen Group

Oct 24, 2016

With the 1,8 billion RMB acquisition, Guan Hao Biotech will become China’s second largest pharmaceutical enterprise and extend ist business into regenerative medicine, cell therapy and other drugs. Huidisen is a leader in cephalosporin production.

China Bio news release, October 24, 2016

Sansheng Pharmaceuticals puts 30,000 L production line for monoclonal antibodies into operation

Oct 21, 2016

Sansheng Pharmaceuticals, a Xinjiang-based company in Henan Province, has completed a 30,000 L production line for monoclonal antibodies, the largest yet in China. According to a spokesman, 80 % of China’s monoclonal antibody drug market of 80 – 100 billion Yen (2015) is provided by foreign enterprises, and Sansheng and two other domestic enterprises account for the remaining 20 %. The growth rate for this market is estimated at ~30 % by 2020.

China Bio news release, October 21, 2016